Here, we evaluated the CD11b and CD169 expression in iCCA specimens through in situ immunohistochemistry (IHC) and validated the prognostic potential of CD11b-CD169-based MRS in iCCA. The gene discussed is SIGLEC1; the disease is infantile convulsions and choreoathetosis.